Originally developed to treat type 2 diabetes, this GLP-1 receptor agonist is now approved and used for effective weight loss helping to regulate appetite, reduce cravings, and support long-term lifestyle change
You may need a lower dose of orforglipron when taking medications that block liver enzymes
Retatrutide , a triple agonist targeting GLP-1, GIP, and glucagon receptors simultaneously, showed up to 24.2% body weight reduction in Phase 2 trials
Appetite reduction usually begins within the first one to two weeks, with noticeable weight loss often appearing after three to eight weeks
Physician Oversight: Prescribed and monitored by licensed providers who specialize in metabolic optimization
So, why does semaglutide make you tired